Description
USP19 modulates transcription of major myofibrillar proteins and is involved in decreased protein synthesis in atrophying skeletal muscle. Inhibition of USP19 could be a novel therapeutic mechanism for the prevention and treatment of muscle protein catabolism (Sundaram et al., 2009). During the cell cycle, USP19 regulates p27 levels by deubiquitylating and stabilizing RNF123, an E3 ubiquitin ligase that ubiquitylates p27 and targets it for proteasomal degradation at the G1 phase. Enhanced degradation of p27 in G1 phase is associated with several cancers, and thus USP19 could be a possible target for oncology research (Lu et al., 2009)